Is Bruker Corporation (BRKR) a Buy, Sell, or Hold?
Bruker Corporation
NASDAQ:BRKR
$59.83 USD
$0.86 (1.46%)
- Volume
- 1.47M
- Average Volume
- 2.51M
- Market Capitalization
- $9.11B
- P/E Ratio
- -250.33
- Dividend Yield
- 0.33%
- Price Target
- $51.50
- Year High
- $64.54
- Year Low
- $28.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $-3.78
- Current Ratio
- $1.55
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Frank H. Laukien |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | BRKR |
| CUSIP | 116794108 |
| CIK | 0001109354 |
| Web | https://www.bruker.com |
| Phone | 978 663 3660 |
| Currency | USD |
| Employees | 11085 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.68 |
| Payout Ratio | -3.78 |
| Current Ratio | 1.55 |
| Quick Ratio | 0.72 |
| Cash Ratio | 0.10 |
Sales & Book Value
| Annual Sales | $3.44B |
| Price / Sales | 2.63 |
| Cash Flow | 0.34 |
| Price / Cash Flow | 177.54 |
| Price / Book | 3.72 |
Price Target and Rating
| Average Stock Price Forecast | $51.50 |
| High Stock Price Forecast | $70.00 |
| Low Stock Price Forecast | $35.00 |
| Forecast Upside/Downside | 16.17% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 33 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.15 |
| Trailing P/E Ratio | -250.33 |
| PEG Ratio | 2.21 |
| P/E Growth | 2.21 |
| Net Income | $-8.6M |
| Net Margin | -0.34% |
| Pretax Margin | 0.40% |
| Return on Equity | -0.51% |
| Return on Assets | -0.19% |
Financials Score
| AltmanZ Score | 2.77 |
| Piotroski Score | 3.00 |
| Working Capital | 748.5M |
| Total Assets | 6.13B |
| Ebit | 74.5M |
| Market Cap | 8.98B |
| Total Liabilities | 3.63B |
Poll Results
About Bruker Corporation (NASDAQ:BRKR) Stock
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain rea ... ction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Bruker Gains 50.3% in a Year: What's Driving the Rally?
2026-06-19 09:36:04
BRKR's rally is fueled by BSI NANO growth, AI-driven metrology demand and gains in preclinical imaging despite tariff pressures.
2026-06-17 12:30:08
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Bruker Corp (BRKR) Stock Up 4.4% and Still Undervalued -- GF Score: 85/100
2026-06-15 20:28:00
On June 15, 2026, Bruker Corp (BRKR) shares rose 4.4% to a current price of $56.63. The stock has shown remarkable performance within the past year, with a 48.7
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-08 09:58:30
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Bruker Signals Growth Pivot as Semiconductor and Overseas Orders Gain Steam
2026-06-06 18:40:50
Bruker NASDAQ: BRKR is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies healthcare conference.
Bruker (BRKR) Up 37.1% Since Last Earnings Report: Can It Continue?
2026-06-05 12:36:14
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?
2026-06-04 13:13:26
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
2026-06-04 07:00:00
WASHINGTON--(BUSINESS WIRE)---- $BRKR #BRKR--At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by.
Frequently Asked Questions
-
What is the current Bruker Corporation (BRKR) stock price?
-
Bruker Corporation(NASDAQ:BRKR) stock price is $59.83 in the last trading session. During the trading session, BRKR stock reached the peak price of $64.54 while $28.53 was the lowest point it dropped to. The percentage change in BRKR stock occurred in the recent session was 1.46% while the dollar amount for the price change in BRKR stock was $0.86.
-
BRKR's industry and sector of operation?
-
The NASDAQ listed BRKR is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of BRKR?
-
Juergen Srega | President of Bruker CALID Group & Bruker Daltonics Division
Gerald N. Herman | Executive Vice President & Chief Financial Officer
Burkhard Prause | President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc.
Frank H. Laukien | Chairman, Chief Executive Officer & President
Thomas Bures | Chief Accounting Officer -
How many employees does BRKR have?
-
Number of BRKR employees currently stands at 11085. BRKR operates from 40 Manning Road, Billerica, MA 01821, US.
-
Link for BRKR official website?
-
Official Website of BRKR is: https://www.bruker.com
-
How do I contact BRKR?
-
BRKR could be contacted at phone #978 663 3660 and can also be accessed through its website. BRKR operates from 40 Manning Road, Billerica, MA 01821, US.
-
How many shares of BRKR are traded daily?
-
The average number of BRKR shares traded daily for last 3 months was 2.51M.
-
What is the market cap of BRKR currently?
-
The market value of BRKR currently stands at $9.11B with its latest stock price at $59.83